Use of pneumococcal polysaccharide vaccine in children: what is the evidence?

Area of Science:

• Immunology
• Vaccinology
• Pediatrics

Background:

• Pneumococcal conjugate vaccines (PCVs) are standard in infant immunization.
• The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for broader serotype coverage in at-risk individuals.
• The use of PPVs, particularly in children, is under ongoing discussion.

Purpose of the Study:

• To review the current evidence on the use of PPV23 in children.
• To assess the benefits and risks of PPV23 in the context of PCV vaccination.
• To explore the implications for protecting at-risk children against pneumococcal infections.

Main Methods:

• Review of existing literature on pneumococcal vaccines.
• Analysis of studies investigating PPV23 efficacy and safety.
• Evaluation of immune responses and potential adverse effects, including B-cell dynamics.

Main Results:

• PPV23 shows limited impact on pneumococcal carriage but may provide some protection against invasive pneumococcal disease (IPD).
• A theoretical risk of memory B-cell depletion exists for PCV serotypes after PPV23 vaccination, especially with revaccination.
• The clinical significance of this B-cell depletion in PCV-primed children is currently unknown.

Conclusions:

• The clinical benefit of PPV23 in at-risk children hinges on age, comorbidities, and serotype immunogenicity.
• The potential for PPV23-induced memory B-cell depletion raises concerns about maintaining optimal protection in susceptible children.
• Further research is needed to clarify the best strategies for sustained protection against IPD in at-risk populations.